UK research team develops new compound with cancer-fighting properties
LEXINGTON, Ky. (Feb. 24, 2024) — University of Kentucky researchers have developed a new class of gold-based compounds that show promise in fighting various types of cancer.
The study, led by UK Markey Cancer Center researcher Samuel Awuah, Ph.D., and published in Dalton Transactions, showed that the compounds could kill cancer cells by disrupting their energy production.
The new compounds work by targeting and shutting down mitochondria, which generate energy for cells. In lab tests, they were effective against several types of cancer cells, including those from breast, ovarian and lung tumors.
The research shows how gold-based compounds can be used in a new way to fight cancer, and potentially other diseases, says Awuah, an associate professor in the UK College of Arts & Sciences Department of Chemistry.
“By creating compounds that remain stable in the body and specifically target cancer cells’ energy source, this opens the doors for the development of new and more effective treatments,” Awuah said.
The study builds upon recent research that shows auranofin — a gold-based drug approved by the FDA in 1985 for treating rheumatoid arthritis — has potential as a cancer therapy.
The research team designed the new compound to be more stable in the body than auranofin through a chemical process they refer to as “stapling.” This method joins gold molecules to other chemical structures in ways that help them resist breaking down inside cells. The increased stability means the compounds could maintain their cancer-fighting properties longer in the body, making them better-suited as a cancer therapy.
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R01CA258421. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
UK HealthCare is the hospitals and clinics of the University of Kentucky. But it is so much more. It is more than 10,000 dedicated health care professionals committed to providing advanced subspecialty care for the most critically injured and ill patients from the Commonwealth and beyond. It also is the home of the state’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, a Level IV Neonatal Intensive Care Unit that cares for the tiniest and sickest newborns, the region’s only Level 1 trauma center and Kentucky’s top hospital ranked by U.S. News & World Report.
As an academic research institution, we are continuously pursuing the next generation of cures, treatments, protocols and policies. Our discoveries have the potential to change what’s medically possible within our lifetimes. Our educators and thought leaders are transforming the health care landscape as our six health professions colleges teach the next generation of doctors, nurses, pharmacists and other health care professionals, spreading the highest standards of care. UK HealthCare is the power of advanced medicine committed to creating a healthier Kentucky, now and for generations to come.